Skip to main content
. 2023 Jun 15;14:1210974. doi: 10.3389/fneur.2023.1210974

Table 1.

Domains assessed in the three IMI-funded consortia RADAR-AD, IDEA-FAST, and Mobilise-D.

Cohorts Trial design Domains assessed Domains assessed digitally
RADAR-AD HC n = 70
PreAD n = 38
ProAD, n = 65
MildAD n = 56		 8 W observation period

  • Activities of daily living

  • Cognitive functions

  • Sleep quality and fatigue

  • Life habits

  • Mobility

  • Social functioning

  • Smartphone proficiency

  • Quality of life

  • Neuropsychiatric symptoms including depression

  • Medical history and medication

  • Physical examination

  • Activities of daily living (apps and wearables)

  • Cognition (apps)

  • Sleep and circadian rhythm (wearables, sleep EEG)

  • Mood and fatigue (app)

  • Mobility SS assessment (IMU)

  • Mobility US assessment (wearables)

  • Social (app)

  • Driving (data logger)
Mobilise-D PD n = 600
MS n = 600
COPD n = 600
PFF n = 600		 1 W observation period every 6 M (5 times in total per participant)

  • Risk of falls

  • Cognitive functions

  • BIA

  • Fatigue

  • Disability

  • Pain

  • Frailty

  • Severity of specific conditions

  • Mobility SS assessment (6MWT, TUG)

  • Mobility US assessment (IMU)
IDEA-FAST HC n = 200
PD n = 500
IBD n = 500
RA n = 200
SLE n = 200
PSS n = 200		 1 W observation period every 6 W (4 times in total per participant)

  • Sleep quality

  • Fatigue (mental vs. physical)

  • Cognitive screening

  • Disability

  • Pain

  • Severity of specific conditions

  • Mobility US assessment

  • Sleep (bed sensors, sleep EEG)

  • ECG and autonomic function

  • Fatigue (app)

  • Cognition (app)

  • Social (app)

AD, Alzheimer’s disease; BIA, body impedance analysis; COPD, Chronic Obstructive Pulmonary Disease; ECG, electrocardiography; EEG, electroencephalography; HC, healthy controls; IBD, Inflammatory bowel disease; IMU, inertial measurement unit; M, months; MildAD, mild-to-moderate AD (dementia, Aβ-positive); MS, multiple Sclerosis; PD, Parkinson’s disease; PFF, Proximal Femur Fracture; preAD, preclinical AD (cognitively normal, Aβ-positive); proAD, prodromal AD (mild cognitive impairment, Aβ-positive); PSS, Primary Sjogren’s syndrome; RA, Rheumatoid Arthritis; SLE, Systemic Lupus Erythematosus; SS; supervised setting; TUG, timed up and go test; US unsupervised setting; W, week(s); 6MWT, 6 min walking test.